FATE THERAPEUTICS INC

FATE · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
218
SEC Filings

Business Summary

PART I Overview We are a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of off-the-shelf cellular immunotherapies to patients. We have pioneered a therapeutic approach that we generally refer to as cellular programming: we create and engineer human induced pluripotent stem cells (iPSCs) to incorporate novel synthetic controls of cell function; after the engineering step that incorporates multiple functional elements into the iPSCs, we generate a clonal m...

Next Earnings

Q2 FY2026 — expected 2026-08-21

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionFATEdiscussed_in_filing Cybersecurity
topic_mentionFATEdiscussed_in_filing Cybersecurity
topic_mentionFATEdiscussed_in_filing Healthcare & Bio
topic_mentionFATEdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-262025-12-310001193125-26-073699EDGAR109K words
2025-03-052024-12-310000950170-25-033510EDGAR—
2024-02-262023-12-310000950170-24-020158EDGAR—
2023-02-282022-12-310000950170-23-005067EDGAR—
2022-02-282021-12-310000950170-22-002293EDGAR—
2021-02-242020-12-310001564590-21-008086EDGAR—
2020-03-022019-12-310001564590-20-008141EDGAR—
2019-03-052018-12-310001564590-19-006258EDGAR—
2018-03-052017-12-310001564590-18-004394EDGAR—
2017-03-162016-12-310001564590-17-004614EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-132025-09-300001193125-25-279096EDGAR68K words
2025-08-122025-06-300000950170-25-107309EDGAR—
2025-05-132025-03-310000950170-25-070285EDGAR—
2024-11-122024-09-300000950170-24-125317EDGAR—
2024-08-132024-06-300000950170-24-096187EDGAR—
2024-05-092024-03-310000950170-24-056869EDGAR—
2023-11-082023-09-300000950170-23-061080EDGAR—
2023-08-082023-06-300000950170-23-039803EDGAR—
2023-05-032023-03-310000950170-23-017175EDGAR—
2022-11-032022-09-300000950170-22-021840EDGAR—
2022-08-032022-06-300000950170-22-014236EDGAR—
2022-05-042022-03-310000950170-22-007389EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-260001193125-26-073689EDGAR4K words
2025-11-130001193125-25-279091EDGAR—
2025-10-270001193125-25-250674EDGAR—
2025-10-140001193125-25-238989EDGAR—
2025-08-120001193125-25-178947EDGAR—
2025-05-300001193125-25-132301EDGAR—
2025-05-130000950170-25-070280EDGAR—
2025-03-050000950170-25-033507EDGAR—
2025-01-060001193125-25-002153EDGAR—
2024-11-290001193125-24-268003EDGAR—

218 total filings indexed. 186 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001434316
TickerFATE
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: d982d086bc31fb1ee3650d120b17c75ce5a036c05ba58533b9ad9d4c9026f4df
parent: d29531a735fac78dfdf3f88109b9c60cffc2b4c39525d32b17a4ef3c79bf0d92
content hash: d22a4b53cc0c7c09158a65f0fdbee16339e4d444c172d70f6793677c6d80de59
signed: 2026-04-13T04:44:59.038Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf